Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network

Tahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, Joost L Boormans, Thorsten H Ecke, Petros D Grivas, Anne E Kiltie, Fredrik Liedberg, Andrea Necchi, Bas W van Rhijn, Florian Roghmann, Marta Sanchez-Carbayo, Bernd J Schmitz-Dräger, Felix Wezel, Ashish M Kamat

Research output: Contribution to journalReview articlepeer-review

Abstract

RATIONALE: Several guidelines exist that address treatment of patients with nonmetastatic muscle-invasive bladder cancer (MIBC). However, most only briefly mention follow-up strategies for patients and hence the treating physician is often left to infer on what the preferred follow-up schema would be for an individual patient. Herein, we aim to synthesize recommendations for follow-up of patients with MIBC for easy reference.

METHODS: A multidisciplinary MIBC expert panel from the International Bladder Cancer Network was assembled to critically assess currently available major guidelines on surveillance of MIBC patients. Recommendations for follow-up were extracted and critically evaluated. Important considerations for guideline assessment included both aspects of oncological and functional follow-up-frequency of visits, the use of different imaging modalities, the role of cytology and molecular markers, and the duration of follow-up.

OUTCOME: An International Bladder Cancer Network expert consensus recommendation was constructed for the follow-up of patients with MIBC based on the currently available evidence-based data.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalUrologic Oncology
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2018

Keywords

  • Consensus
  • Disease Management
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Urinary Bladder Neoplasms/pathology

Fingerprint Dive into the research topics of 'Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network'. Together they form a unique fingerprint.

Cite this